Mir210 (microRNA 210) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Mir210 (microRNA 210) Rattus norvegicus
Symbol: Mir210
Name: microRNA 210
RGD ID: 2314887
Description: Predicted to enable mRNA 3'-UTR binding activity and mRNA base-pairing translational repressor activity. Involved in several processes, including cellular response to hydrogen peroxide; regulation of apoptotic process; and response to ischemia. Biomarker of Parkinson's disease and middle cerebral artery infarction. Orthologous to human MIR210 (microRNA 210); INTERACTS WITH (R)-lipoic acid; acetic acid; aflatoxin B1.
Type: ncrna (Ensembl: miRNA)
Previously known as: microRNA mir-210; rno-mir-210
RGD Orthologs
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21196,326,343 - 196,326,452 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1196,326,337 - 196,326,454 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1204,671,839 - 204,671,948 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01211,798,505 - 211,798,614 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01204,472,641 - 204,472,750 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01214,208,355 - 214,208,464 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.01221,125,894 - 221,126,003 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41201,415,656 - 201,415,765 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1193,960,215 - 193,960,324 (-)NCBICelera
Cytogenetic Map1q41NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
BMP signaling pathway  (ISO)
cellular response to hydrogen peroxide  (IMP)
cellular response to hypoxia  (IEP)
cellular response to leukemia inhibitory factor  (ISO)
cellular response to lipopolysaccharide  (ISO)
hypoxia-inducible factor-1alpha signaling pathway  (ISO)
miRNA-mediated gene silencing by inhibition of translation  (ISO)
miRNA-mediated gene silencing by mRNA destabilization  (ISO)
miRNA-mediated post-transcriptional gene silencing  (ISO)
negative regulation of activin receptor signaling pathway  (ISO)
negative regulation of apoptotic signaling pathway  (ISO)
negative regulation of BMP signaling pathway  (ISO)
negative regulation of cardiac muscle cell apoptotic process  (IMP)
negative regulation of cytokine production  (ISO)
negative regulation of mitochondrial electron transport, NADH to ubiquinone  (ISO)
negative regulation of vascular associated smooth muscle cell apoptotic process  (ISO)
positive regulation of angiogenesis  (ISO)
positive regulation of blood vessel endothelial cell migration  (ISO)
positive regulation of cell migration  (ISO)
positive regulation of glucose catabolic process to lactate via pyruvate  (ISO)
positive regulation of iron ion import across plasma membrane  (ISO)
positive regulation of neuron apoptotic process  (IMP)
positive regulation of osteoblast differentiation  (ISO)
regulation of cardiac muscle cell apoptotic process  (IMP)
regulation of cellular response to hypoxia  (ISO)
response to hypoxia  (IEP,IMP)
response to ischemia  (IEP)
tube formation  (ISO)

Molecular Function


References - curated
# Reference Title Reference Citation
1. Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia. Adel S, etal., Gene. 2017 Jan 5;596:105-109. doi: 10.1016/j.gene.2016.10.014. Epub 2016 Oct 13.
2. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. Chang W, etal., J Vet Sci. 2013;14(1):69-76. doi: 10.4142/jvs.2013.14.1.69. Epub 2013 Feb 5.
3. MicroRNA-210 alleviates oxidative stress-associated cardiomyocyte apoptosis by regulating BNIP3. Diao H, etal., Biosci Biotechnol Biochem. 2017 Sep;81(9):1712-1720. doi: 10.1080/09168451.2017.1343118. Epub 2017 Jun 29.
4. MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. Gan L, etal., Medicine (Baltimore). 2017 Jul;96(28):e7515. doi: 10.1097/MD.0000000000007515.
5. Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema. Hu P, etal., Pak J Med Sci. 2022 May-Jun;38(5):1327-1332. doi: 10.12669/pjms.38.5.5092.
6. Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice. Huang L, etal., Exp Neurol. 2018 Feb;300:41-50. doi: 10.1016/j.expneurol.2017.10.024. Epub 2017 Oct 27.
7. Analysis of differential expression of hypoxia-inducible microRNA-210 gene targets in mild and severe preeclamptic patients. Jairajpuri DS, etal., Noncoding RNA Res. 2021 Mar 9;6(1):51-57. doi: 10.1016/j.ncrna.2021.03.001. eCollection 2021 Mar.
8. The MicroRNA-210/Casp8ap2 Pathway Alleviates Hypoxia-Induced Injury in Myocardial Cells by Regulating Apoptosis and Autophagy. Li K, etal., Heart Surg Forum. 2020 Oct 21;23(6):E797-E802. doi: 10.1532/hsf.3173.
9. Protection of Human Umbilical Vein Endothelial Cells against Oxidative Stress by MicroRNA-210. Li T, etal., Oxid Med Cell Longev. 2017;2017:3565613. doi: 10.1155/2017/3565613. Epub 2017 Mar 7.
10. Expression of miR-210 in senile COPD complicating primary lung cancer. Li XX, etal., Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):38-42.
11. Modified Renshen Yangrong decoction enhances angiogenesis in ischemic stroke through promotion of MicroRNA-210 expression by regulating the HIF/VEGF/Notch signaling pathway. Liang C, etal., Brain Behav. 2021 Aug;11(8):e2295. doi: 10.1002/brb3.2295. Epub 2021 Aug 1.
12. MicroRNA-210 downregulates TET2 and contributes to inflammatory response in neonatal hypoxic-ischemic brain injury. Ma Q, etal., J Neuroinflammation. 2021 Jan 5;18(1):6. doi: 10.1186/s12974-020-02068-w.
13. Inhibition of microRNA-210 provides neuroprotection in hypoxic-ischemic brain injury in neonatal rats. Ma Q, etal., Neurobiol Dis. 2016 May;89:202-12. doi: 10.1016/j.nbd.2016.02.011. Epub 2016 Feb 11.
14. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. McCormick RI, etal., Br J Cancer. 2013 Mar 19;108(5):1133-42. doi: 10.1038/bjc.2013.56. Epub 2013 Feb 28.
15. MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Muralimanoharan S, etal., Placenta. 2012 Oct;33(10):816-23. doi: 10.1016/j.placenta.2012.07.002. Epub 2012 Jul 26.
16. miR-210 Participates in Hepatic Ischemia Reperfusion Injury by Forming a Negative Feedback Loop With SMAD4. Pan WM, etal., Hepatology. 2020 Dec;72(6):2134-2148. doi: 10.1002/hep.31221. Epub 2020 Sep 2.
17. Impact of microRNA-210 on wound healing among the patients with diabetic foot ulcer. Pichu S, etal., PLoS One. 2021 Jul 22;16(7):e0254921. doi: 10.1371/journal.pone.0254921. eCollection 2021.
18. Neuroprotective effects of microRNA-210 on hypoxic-ischemic encephalopathy. Qiu J, etal., Biomed Res Int. 2013;2013:350419. doi: 10.1155/2013/350419. Epub 2013 Sep 9.
19. The lower expression of circulating miR-210 and elevated serum levels of HIF-1α in ischemic stroke; Possible markers for diagnosis and disease prediction. Rahmati M, etal., J Clin Lab Anal. 2021 Dec;35(12):e24073. doi: 10.1002/jcla.24073. Epub 2021 Oct 28.
20. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
21. Circulating MicroRNA-210 Concentrations in Patients with Acute Heart Failure: Data from the Akershus Cardiac Examination 2 Study. Rutkovskiy A, etal., Clin Chem. 2021 Jun 1;67(6):889-898. doi: 10.1093/clinchem/hvab030.
22. Prognostic value of circulating microRNA-210 levels in patients with moderate to severe aortic stenosis. Røsjø H, etal., PLoS One. 2014 Mar 13;9(3):e91812. doi: 10.1371/journal.pone.0091812. eCollection 2014.
23. Protein Deimination Signatures in Plasma and Plasma-EVs and Protein Deimination in the Brain Vasculature in a Rat Model of Pre-Motor Parkinson's Disease. Sancandi M, etal., Int J Mol Sci. 2020 Apr 15;21(8). pii: ijms21082743. doi: 10.3390/ijms21082743.
24. Insulin protects H9c2 rat cardiomyoblast cells against hydrogen peroxide-induced injury through upregulation of microRNA-210. Shi YF, etal., Free Radic Res. 2015;49(9):1147-55. doi: 10.3109/10715762.2015.1050588. Epub 2015 Jun 22.
25. MicroRNA-210 Controls Mitochondrial Metabolism and Protects Heart Function in Myocardial Infarction. Song R, etal., Circulation. 2022 Apr 12;145(15):1140-1153. doi: 10.1161/CIRCULATIONAHA.121.056929. Epub 2022 Mar 17.
26. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection. Su Y, etal., Clin Epigenetics. 2016 Oct 19;8:109. doi: 10.1186/s13148-016-0275-5. eCollection 2016.
27. Potential role of circulating microRNAs as early markers of preeclampsia. Ura B, etal., Taiwan J Obstet Gynecol. 2014 Jun;53(2):232-4. doi: 10.1016/j.tjog.2014.03.001.
28. The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke. Wang LQ, etal., Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4756-4760.
29. Combined prediction of miR-210 and miR-374a for severity and prognosis of hypoxic-ischemic encephalopathy. Wang Z, etal., Brain Behav. 2017 Dec 30;8(1):e00835. doi: 10.1002/brb3.835. eCollection 2018 Jan.
30. Association of MicroRNA-210 and MicroRNA-155 with severity of preeclampsia. Youssef HMG and Marei ES, Pregnancy Hypertens. 2019 Jul;17:49-53. doi: 10.1016/j.preghy.2019.05.010. Epub 2019 May 10.
31. Hypoxia-Induced miR-210 Is Necessary for Vascular Regeneration upon Acute Limb Ischemia. Zaccagnini G, etal., Int J Mol Sci. 2019 Dec 24;21(1):129. doi: 10.3390/ijms21010129.
32. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Zeng L, etal., Front Biosci (Elite Ed). 2011 Jun 1;3(4):1265-72. doi: 10.2741/e330.
33. Gingerol ameliorates neuronal damage induced by hypoxia-reoxygenation via the miR-210/brain-derived neurotrophic factor axis. Zhai Y, etal., Kaohsiung J Med Sci. 2022 Apr;38(4):367-377. doi: 10.1002/kjm2.12486. Epub 2021 Dec 28.
34. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice. Zhang H, etal., J Nanobiotechnology. 2019 Feb 19;17(1):29. doi: 10.1186/s12951-019-0461-7.
35. Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker. Zhang Q, etal., Biomarkers. 2013 Feb;18(1):23-9. doi: 10.3109/1354750X.2012.728624. Epub 2012 Oct 10.
36. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. Zhang Y, etal., J Cell Mol Med. 2012 Feb;16(2):249-59. doi: 10.1111/j.1582-4934.2011.01291.x.
Additional References at PubMed
PMID:16381832   PMID:16766679   PMID:17604727   PMID:19520079   PMID:19721136   PMID:20403161   PMID:20439489   PMID:21247879   PMID:21698002   PMID:22482882   PMID:22833359   PMID:23039253  
PMID:23097335   PMID:23154340   PMID:23608607   PMID:25168379   PMID:25323830   PMID:25503465   PMID:25783636   PMID:26244598   PMID:26276312   PMID:27530798   PMID:28123348   PMID:28678929  
PMID:28948298   PMID:29032377   PMID:29387863   PMID:29484401   PMID:29710553   PMID:29723850   PMID:30656514   PMID:30668175   PMID:30947960   PMID:30964182   PMID:31257474   PMID:31300734  
PMID:31596148   PMID:32388695   PMID:32590394   PMID:32638262   PMID:33000559   PMID:33215409   PMID:33882492   PMID:33937412   PMID:33994501   PMID:34545968   PMID:34678242   PMID:34914300  
PMID:36272206   PMID:36541246   PMID:37198572  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21196,326,343 - 196,326,452 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1196,326,337 - 196,326,454 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1204,671,839 - 204,671,948 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01211,798,505 - 211,798,614 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01204,472,641 - 204,472,750 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01214,208,355 - 214,208,464 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.01221,125,894 - 221,126,003 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41201,415,656 - 201,415,765 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1193,960,215 - 193,960,324 (-)NCBICelera
Cytogenetic Map1q41NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh3811568,089 - 568,198 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl11568,089 - 568,198 (-)EnsemblGRCh38hg38GRCh38
GRCh3711568,089 - 568,198 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 3611558,088 - 558,197 (-)NCBINCBI36Build 36hg18NCBI36
Celera11630,746 - 630,855 (-)NCBICelera
Cytogenetic Map11p15.5NCBI
HuRef11383,108 - 383,217 (-)NCBIHuRef
CHM1_111567,011 - 567,120 (-)NCBICHM1_1
T2T-CHM13v2.011615,087 - 615,196 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm397140,801,297 - 140,801,406 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl7140,801,297 - 140,801,406 (-)EnsemblGRCm39 Ensembl
GRCm387141,221,384 - 141,221,493 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl7141,221,384 - 141,221,493 (-)EnsemblGRCm38mm10GRCm38
MGSCv377148,407,283 - 148,407,392 (-)NCBIGRCm37MGSCv37mm9NCBIm37
Celera7141,015,149 - 141,015,258 (-)NCBICelera
Cytogenetic Map7F5NCBI
cM Map786.52NCBI

miRNA Target Status

Predicted Targets
Summary Value
Count of predictions:11369
Count of gene targets:6603
Count of transcripts:7152
Interacting mature miRNAs:rno-miR-210-3p, rno-miR-210-5p
Prediction methods:Microtar, Miranda, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
1578780Cm52Cardiac mass QTL 523.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)181591954219808434Rat
1331749Hrtrt11Heart rate QTL 112.973heart pumping trait (VT:2000009)heart rate (CMO:0000002)194494440198211706Rat
70209Niddm23Non-insulin dependent diabetes mellitus QTL 232.82blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)194494440198324465Rat
731168Bp154Blood pressure QTL 1543.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)194642644214537671Rat
1354591Cm36Cardiac mass QTL 364.1heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1102813953201278233Rat
1354615Cm32Cardiac mass QTL 325.2heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)1102813953201278233Rat
1354606Bp246Blood pressure QTL 2463.6arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)1102813953218753816Rat
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
631205Bp196Blood pressure QTL 19640.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118944897199050459Rat
631549Bp89Blood pressure QTL 895.7arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1123350581201284552Rat
1598853Memor3Memory QTL 34.5exploratory behavior trait (VT:0010471)total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443)1143506580212458660Rat
61348Bp30Blood pressure QTL 302.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1144017057197814409Rat
70160Bw18Body weight QTL 185.7body mass (VT:0001259)body weight (CMO:0000012)1144267353196383668Rat
737828Hcas3Hepatocarcinoma susceptibility QTL 34.9liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)1144267353222987745Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
7771612Cm80Cardiac mass QTL 808.4heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)1149448574221264292Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354602Bw35Body weight QTL 3512.2body mass (VT:0001259)body weight (CMO:0000012)1151162512201278233Rat
1354620Kidm19Kidney mass QTL 194kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512201278233Rat
1354634Kidm12Kidney mass QTL 123.9kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)1151162512201278233Rat
1354636Lmblg1Limb length QTL 16.4tibia length (VT:0004357)tibia length (CMO:0000450)1151162512201278233Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1358886Bp260Blood pressure QTL 2603.67arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1151162766225824951Rat
61343Bp28Blood pressure QTL 28arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1151646613196646613Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
2303622Vencon6Ventilatory control QTL 60.001respiration trait (VT:0001943)respiration rate (CMO:0000289)1154561505199561505Rat
4889428Stresp24Stress response QTL 240.05heart pumping trait (VT:2000009)absolute change in electrocardiographic low frequency R-R spectral component to high frequency R-R spectral component ratio (CMO:0002162)1155866514200866514Rat
1354618Kidm15Kidney mass QTL 155kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)1156677124201278233Rat
2312420Pur17Proteinuria QTL 177.10.0001urine protein amount (VT:0005160)urine total protein excretion rate (CMO:0000756)1156677124218753816Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
61347Bp197Blood pressure QTL 1974.2arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)1158633083203633083Rat
2292222Bp307Blood pressure QTL 3073.060.0014arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393213533942Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
619613Bp77Blood pressure QTL 770.01arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164747424209747424Rat
619613Bp77Blood pressure QTL 770.01arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1164747424209747424Rat
1354653Despr9Despair related QTL 90.00019locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)1167909849212909849Rat
619614Bp78Blood pressure QTL 780.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1169112897197261052Rat
619614Bp78Blood pressure QTL 780.001arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1169112897197261052Rat
61341Bp26Blood pressure QTL 26arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1169537671214537671Rat
724562Rends1Renal damage susceptibility QTL 10.05kidney glomerulus integrity trait (VT:0010546)index of glomerular damage (CMO:0001135)1169537671214537671Rat
1358294Bw37Body weight QTL 3750.000011body mass (VT:0001259)body weight (CMO:0000012)1171310381216310381Rat
2293689Bss47Bone structure and strength QTL 477.250.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra trabecular cross-sectional area (CMO:0001692)1171629477216629477Rat
2293693Bss22Bone structure and strength QTL 2233.520.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1171629477216629477Rat
2300161Bmd43Bone mineral density QTL 438.40.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1171629477216629477Rat
2300174Bmd42Bone mineral density QTL 428.40.0001lumbar vertebra mineral mass (VT:0010511)bone mineral density (CMO:0001226)1171629477216629477Rat
2300187Bmd41Bone mineral density QTL 418.90.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1171629477216629477Rat
2293654Bss30Bone structure and strength QTL 3032.650.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1171629477216629477Rat
2293673Bss27Bone structure and strength QTL 2718.630.0001femur morphology trait (VT:0000559)femur midshaft cortical cross-sectional area (CMO:0001663)1171629477216629477Rat
2293677Bss41Bone structure and strength QTL 419.380.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1171629477216629477Rat
1549830Bss1Bone structure and strength QTL 14.8femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1172609619217609619Rat
631214Bw61Body weight QTL613.40.0001intramuscular adipose amount (VT:0010044)intramuscular fat area (CMO:0001162)1173108781218108781Rat
631670Iddm10Insulin dependent diabetes mellitus QTL 101.9blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1174133260196383668Rat
70163Bw20Body weight QTL 205.1body mass (VT:0001259)body weight (CMO:0000012)1174133260219133260Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1600380Niddm70Non-insulin dependent diabetes mellitus QTL 703.10.0008blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1176550523221550523Rat
10059600Bp378Blood pressure QTL 3783.080.05arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1176869060221869060Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
1558658Bw59Body weight QTL 593.50.0003body mass (VT:0001259)body weight (CMO:0000012)1178784622223784622Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
1302787Stl25Serum triglyceride level QTL 252.70.0073blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)1180359209210702199Rat
6903303Scl34Serum cholesterol QTL 342.50.0033blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)1180359209218108781Rat
737977Bp160Blood pressure QTL 1600.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1181133855226133855Rat
61378Bp43Blood pressure QTL 4322.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1181746937196383668Rat
724559Pancm1Pancreatic morphology QTL 17.1islet of Langerhans morphology trait (VT:0005215)pancreatic islet damage composite score (CMO:0001156)1181759564214537555Rat
2293083Iddm25Insulin dependent diabetes mellitus QTL 254.18blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1181829673224569684Rat
634312Bp143Blood pressure QTL 14330.0002arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1182623426219932796Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1184550676229550676Rat
1300145Rf7Renal function QTL 72.96urine creatinine amount (VT:0010540)urine creatinine level (CMO:0000125)1185145134221264292Rat
1359018Hrtrt20Heart rate QTL 203.08heart pumping trait (VT:2000009)heart rate (CMO:0000002)1185356336202902618Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1185356336231689108Rat
1582206Kidm33Kidney mass QTL 336.9kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1188377360224054420Rat
6480780Insul18Insulin level QTL 184.11blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1189607473200611765Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
631260Tcas2Tongue tumor susceptibility QTL 24.93tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)1192485903199050587Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
634338Hcar4Hepatocarcinoma resistance QTL 44.6liver integrity trait (VT:0010547)liver tumorous lesion number to liver area ratio (CMO:0001210)1193422268214537671Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1358292Cm37Cardiac mass QTL 376.20.00000081heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat



RefSeq Acc Id: ENSRNOT00000053739
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1196,326,337 - 196,326,454 (+)Ensembl
RefSeq Acc Id: NR_031923
Rat AssemblyChrPosition (strand)Source
mRatBN7.21196,326,343 - 196,326,452 (-)NCBI
Rnor_6.01214,208,355 - 214,208,464 (-)NCBI
Rnor_5.01221,125,894 - 221,126,003 (-)NCBI
RGSC_v3.41201,415,656 - 201,415,765 (-)RGD
Celera1193,960,215 - 193,960,324 (-)RGD

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2314887 AgrOrtholog
BioCyc Gene G2FUF-56968 BioCyc
Ensembl Genes ENSRNOG00000035616 Ensembl
miRBase MI0000950 ENTREZGENE
NCBI Gene 100314053 ENTREZGENE
PhenoGen Mir210 PhenoGen
RNAcentral URS000055128B RNACentral
  URS000075B979 RNACentral
  URS000075E625 RNACentral

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2015-03-25 Mir210  microRNA 210  Mir210  microRNA mir-210  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2009-12-04 Mir210  microRNA mir-210      Symbol and Name status set to provisional 70820 PROVISIONAL